Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 16 at 2:00 PM EDT

Register Free →

This Solicitation opportunity from Department Of Defense was posted on May 31, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

ATENOLOL TABLETS, US

Closed
SPE2DP-26-T-3590Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

AI Contract Overview

Show more

The contract is for the procurement of ATENOLOL TABLETS, 25 MG, in quantities of 100 per unit, identified by NSN 6505-01-336-6196, under solicitation SPE2DP-26-T-3590 issued by the Department of Defense’s Medical Supply Chain Pharm FSA. The item is a pharmaceutical regulated by the FDA and must meet a mandatory non-extendable shelf life of 36 months as a Type I (Code Q) item. Delivery is required FOB destination within 20 days after order date to Fort Bragg, North Carolina, with zero tolerance for quantity variance. Packaging must conform to commercial standards using sealed unit containers and suitable exterior shipping containers, with all markings compliant with Medical Marking Standard No. 1, which replaces MIL-STD-129, and preservation and packing must adhere to MIL-STD-2073-1E. The contract incorporates technical and quality requirements from the DLA Master List of Technical and Quality Requirements, referenced by R and I numbers, and requires compliance with DFARS 252.225-7001 for the Buy American Act and applicable domestic material restrictions, including the Berry Amendment. Contractors must use Wide Area Workflow for payment submissions and follow specific invoicing procedures based on line item type. The solicitation is not a small business set-aside but mandates representations regarding small business status, socioeconomic certifications, and compliance with combating trafficking, equal opportunity, and cybersecurity requirements including NIST SP 800-171 and safeguarding of information systems. Offerors must be registered in the System for Award Management, provide a CAGE code, and comply with all applicable FAR and DFARS clauses, including deviations for 2026-00038 affecting several clauses related to contract type, simplified acquisitions, and SAM maintenance. The contract applies to approved manufacturers including McKesson, Mylan, and Teva, with submission due by June 8, 2026, and is subject to inspection and acceptance at the destination point.

General Info

Procurement of Atenolol Tablets, 25 mg, 100 per bottle, delivery to Fort Bragg in 20 days.

Agency

Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSAView Agency

NAICS

325412 - Pharmaceutical Preparation ManufacturingView NAICS

Place of Performance

2530 TAYLOR STREET BLDG NUMBER 2530, FORT BRAGG, NC, 28310, USA

Set-Aside

NONE

Documents

(1)

RFQ SPE2DP-26-T-3590 Medical Supply Chain Pharma

PDFrfq

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseClosed
Posted

Solicitation

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA
Contacts1 person available
OfficeUSA
Organization / Agency
Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA
View Agency Profile
Office AddressUSA

Full Description

Show more
ATENOLOL TABLETS,US
ATENOLOL TABLETS,25 MG,100S
RP001: DLA PACKAGING REQUIREMENTS FOR PROCUREMENT
RA001: THIS DOCUMENT INCORPORATES TECHNICAL AND/OR QUALITY REQUIREMENTS
(IDENTIFIED BY AN 'R' OR AN 'I' NUMBER) SET FORTH IN FULL TEXT IN THE
DLA MASTER LIST OF TECHNICAL AND QUALITY REQUIREMENTS FOUND ON THE WEB
AT:
http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx
FOR SIMPLIFIED ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE SOLICITATION ISSUE DATE OR THE AWARD DATE CONTROLS. FOR LARGE ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE RFP ISSUE DATE APPLIES UNLESS A SOLICITATION AMENDMENT INCORPORATES A FOLLOW-ON REVISION, IN WHICH CASE THE AMENDMENT DATE CONTROLS.
This device or drug is regulated by the FDA. Note to Buyers: The contracting official shall send a referral in EBS to the product specialist for confirmation. Please include bidder name and bidder contact information, manufacturer name, manufacturer part number, and item description. 1 BT = 100 TT RS020: Shelf-life requirement RS001 for a TYPE I (CODE Q) item with a shelf life of 36 months (non-extendable) applies to this item.
APPLICABLE TO ALL MEDICAL ACQUISITIONS:
PACKAGING AND PACKING SHALL BE COMMERCIAL AS
SPECIFIED IN THE PROCUREMENT DOCUMENT.
EACH COMPLETE UNIT SHALL BE PROPERLY PACKAGED
IN A SUITABLE SEALED UNIT CONTAINER CAPABLE
OF PROTECTING THE CONTENTS FROM DAMAGE AND/OR
BREAKAGE.
UNITS SHALL BE PACKED IN SUITABLE COMMERCIAL
EXTERIOR (SHIPPING) CONTAINERS (EXPORT WHEN
NECESSARY) WHICH SHALL INSURE ACCEPTANCE AND
SAFE DELIVERY BY COMMON OR OTHER CARRIER, AT
THE LOWEST RATE, TO POINT OF DELIVERY CALLED
FOR IN THE CONTRACT OR ORDER.
MATERIAL MUST BE MARKED IAW MEDICAL MARKING
STANDARD NO. 1. THIS SUPERCEDES ALL REFERENCES
TO MIL-STD-129.
COPIES OF MEDICAL MARKING STANDARD NO. 1
(MMS NO. 1) MAY BE OBTAINED BY CONTACTING DLA
TROOP SUPPORT VIA EMAIL TO fssb@dla.mil. MMS NO. 1 IS ALSO AVAILABLE ONLINE AT: https://www.dla.mil/Logistics-Operations/Packaging/
RD003, COVERED DEFENSE INFORMATION POTENTIALLY APPLIES
SHALL BE MARKED IAW THE LATEST EDITION OF
SPE2DP-26-T-3590
SECTION B
THE MEDICAL MARKING STANDARD NO. 1.
MMS NO. 1 IS AVAILABLE ONLINE AT:
https://www.dla.mil/Logistics-Operations/Packaging/
MCKESSON CORPORATION 34WR5 P/N 463649 MYLAN PHARMACEUTICALS INC 3KJG9 P/N NDC00378-0218-01 TEVA PHARMACEUTICALS USA, INC. 3V8D7 P/N NDC00093-0787-01
DLA issues this document using the DoD authorized unit of issue, please refer to the following URL to determine the corresponding ANSI X12 unit of issue.
https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.dla.mil%2FPortals%2F104%2FDocuments% 2FDLMS%2FeApplications%2FLogDataAdmin%2FUnitofIssueandPurchaseUnit.xlsx&wdOrigin=BROWSELINK
CLIN PR PRLI UI QUANTITY UNIT PRICE TOTAL PRICE.
0001 7016959368 0001 BT 1.000
NSN/MATERIAL:6505013366196
DELIVERY (IN DAYS):0020
DELIVER FOB: DESTINATION
QTY VARIANCE: PLUS 0% MINUS 0%
INSPECTION POINT: DESTINATION
ACCEPTANCE POINT: DESTINATION
PREP FOR DELIVERY:
PKGING DATA MIL-STD-2073-1E
SPECIAL NSN/Part Number: 6505-01-336-6196 Quantity: 1 BT Purchase Request: 7016959368QTY: 1 Delivery: 20 days ADO

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 650+ contractors already using CLEATUS